BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cipargamin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cipargamin\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07811908-11260@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20270204
DTEND;VALUE=DATE:20270205
SUMMARY:Cipargamin: Phase 2 readout est. (NCT07811908)
DESCRIPTION:Cipargamin\, phase 2\, Malaria.\nStudy: Platform Study to Evalu
 ate the Efficacy and Safety of Anti-malarial Agents in Participants With U
 ncomplicated Plasmodium Falciparum Malaria (Cohort C2)\nEstimated primary 
 completion: 4 February 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/cipargamin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07811908
URL:https://assetmemo.bio/drug/cipargamin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
